These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22030027)

  • 41. Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase.
    Hebeisen P; Haap W; Kuhn B; Mohr P; Wessel HP; Zutter U; Kirchner S; Ruf A; Benz J; Joseph C; Alvarez-Sánchez R; Gubler M; Schott B; Benardeau A; Tozzo E; Kitas E
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3237-42. PubMed ID: 21550236
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of novel PI3Kγ/δ inhibitors as potential agents for inflammation.
    Ellard K; Sunose M; Bell K; Ramsden N; Bergamini G; Neubauer G
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4546-9. PubMed ID: 22738635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.
    Huth JR; Park C; Petros AM; Kunzer AR; Wendt MD; Wang X; Lynch CL; Mack JC; Swift KM; Judge RA; Chen J; Richardson PL; Jin S; Tahir SK; Matayoshi ED; Dorwin SA; Ladror US; Severin JM; Walter KA; Bartley DM; Fesik SW; Elmore SW; Hajduk PJ
    Chem Biol Drug Des; 2007 Jul; 70(1):1-12. PubMed ID: 17630989
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.
    Kuo GH; Prouty C; DeAngelis A; Shen L; O'Neill DJ; Shah C; Connolly PJ; Murray WV; Conway BR; Cheung P; Westover L; Xu JZ; Look RA; Demarest KT; Emanuel S; Middleton SA; Jolliffe L; Beavers MP; Chen X
    J Med Chem; 2003 Sep; 46(19):4021-31. PubMed ID: 12954055
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha.
    Richard DJ; Verheijen JC; Yu K; Zask A
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2654-7. PubMed ID: 20223664
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
    D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
    J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.
    Nowak P; Cole DC; Brooijmans N; Bursavich MG; Curran KJ; Ellingboe JW; Gibbons JJ; Hollander I; Hu Y; Kaplan J; Malwitz DJ; Toral-Barza L; Verheijen JC; Zask A; Zhang WG; Yu K
    J Med Chem; 2009 Nov; 52(22):7081-9. PubMed ID: 19848404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design of new benzoxazole-2-thione-derived inhibitors of Streptococcus pneumoniae hyaluronan lyase: structure of a complex with a 2-phenylindole.
    Rigden DJ; Botzki A; Nukui M; Mewbourne RB; Lamani E; Braun S; von Angerer E; Bernhardt G; Dove S; Buschauer A; Jedrzejas MJ
    Glycobiology; 2006 Aug; 16(8):757-65. PubMed ID: 16638841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer.
    Dong Q; Dougan DR; Gong X; Halkowycz P; Jin B; Kanouni T; O'Connell SM; Scorah N; Shi L; Wallace MB; Zhou F
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1315-9. PubMed ID: 21310613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
    Thomas M; Owen C
    Curr Opin Pharmacol; 2008 Jun; 8(3):267-74. PubMed ID: 18394961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
    Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B
    J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K.
    Verheijen JC; Yu K; Toral-Barza L; Hollander I; Zask A
    Bioorg Med Chem Lett; 2010 Jan; 20(1):375-9. PubMed ID: 19897362
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibitors of histone demethylases.
    Lohse B; Kristensen JL; Kristensen LH; Agger K; Helin K; Gajhede M; Clausen RP
    Bioorg Med Chem; 2011 Jun; 19(12):3625-36. PubMed ID: 21596573
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
    Hilton S; Naud S; Caldwell JJ; Boxall K; Burns S; Anderson VE; Antoni L; Allen CE; Pearl LH; Oliver AW; Wynne Aherne G; Garrett MD; Collins I
    Bioorg Med Chem; 2010 Jan; 18(2):707-18. PubMed ID: 20022510
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-guided discovery of cyclin-dependent kinase inhibitors.
    Fischmann TO; Hruza A; Duca JS; Ramanathan L; Mayhood T; Windsor WT; Le HV; Guzi TJ; Dwyer MP; Paruch K; Doll RJ; Lees E; Parry D; Seghezzi W; Madison V
    Biopolymers; 2008 May; 89(5):372-9. PubMed ID: 17937404
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors.
    Terstiege I; Perry M; Petersen J; Tyrchan C; Svensson T; Lindmark H; Öster L
    Bioorg Med Chem Lett; 2017 Feb; 27(3):679-687. PubMed ID: 28017532
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design.
    Alfaro-Lopez J; Yuan W; Phan BC; Kamath J; Lou Q; Lam KS; Hruby VJ
    J Med Chem; 1998 Jun; 41(13):2252-60. PubMed ID: 9632358
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.
    Nacht M; Qiao L; Sheets MP; St Martin T; Labenski M; Mazdiyasni H; Karp R; Zhu Z; Chaturvedi P; Bhavsar D; Niu D; Westlin W; Petter RC; Medikonda AP; Singh J
    J Med Chem; 2013 Feb; 56(3):712-21. PubMed ID: 23360348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl)quinoxalines as PI3Kα inhibitors.
    Wu P; Su Y; Liu X; Zhang L; Ye Y; Xu J; Weng S; Li Y; Liu T; Huang S; Yang B; He Q; Hu Y
    Eur J Med Chem; 2011 Nov; 46(11):5540-8. PubMed ID: 21945250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.